Attilio Maurano

Attilio Maurano

Auto-generated profile, based on publicly available information

Attilio Maurano

Digestive Endoscopy Unit, San Giovanni di Dio e Ruggi d’Aragona University Hospital, Gaetano Fucito Location, Mercato San Severino, Salerno, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in ACG Case Reports Journal
Verified
Journal Article
Open access
Mario GagliardiMario Gagliardi
Mario Gagliardi
GOGiovanni Oliviero
Giovanni Oliviero
MFMichele Fusco
Michele Fusco
MNMarco Napoli
Marco Napoli
ASAndrea Sica
Andrea Sica
CZClaudio Zulli
Claudio Zulli
Endoscopic sphincterotomy (ES) is commonly performed during endoscopic retrograde cholangiopancreatography, and bleeding is a severe adverse event. PuraStat is a peptide developed as a hemostatic agent for endoscopy. We report its use as a hemostatic strategy in post-ES bleeding refractory to combined hemostasis. A patient with choledocholithiasis underwent endoscopic retrograde cholangiopancreatography for stone removal. After the ES, severe bleeding refractory to the injection of diluted epinephrine around the bleeding source and metal stent placement occurred. Hemostasis was achieved with the application of the hemostatic gel. We reported the use of novel self-assembling hemostatic gel as an effective therapeutic tool for post-ES refractory bleeding.

10 August 2021 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
Mario GagliardiMario Gagliardi
Mario Gagliardi
MSMariano Sica
Mariano Sica
GOGiovanni Oliviero
Giovanni Oliviero
AMAttilio Maurano
Attilio Maurano
CZClaudio Zulli
Claudio Zulli
A 49-years-old woman with a recent history of tenesmus, constipation, abdominal and rectal pain referred to our Unit. There was no previous history of rectal bleeding or a family history of gastrointestinal diseases. Laboratory tests showed haemoglobin 10.9 g/dl, MCV 72fl, ferritin 18 U/l. Physical examination was normal. The patient underwent a colonoscopy which identified a single ulcer of 2.5 cm of diameter without bleeding signs in the distal rectum, 4 cm from the anal margin. Histopathological examination revealed shallow ulceration with fibrosis in lamina propria. We decided to treat the ulcer with one application of Purastat. Four weeks later, a follow-up colonoscopy revealed a complete mucosal healing with only mild residual mucosal erythema. Solitary Rectal Ulcer Syndrome (SRUS) is an uncommon benign proctologic disease usually affecting young adults with a prevalence of 1:100.000 per year, equally affecting women and men with a slight predominance in young women. SRUS is characterized by chronic rectal pain and bleeding, constipation, incomplete evacuation, tenesmus and mucous discharge impairing the patients’ quality of life. In past years several topical agents have been used reporting clinical improvements, also if none of them has been evaluated in prospective controlled trials. Purastat (3D-Matrix Europe SAS, France) is a novel self-assembling peptide developed as a haemostatic agent for endoscopic and surgical procedures. In addition to the known haemostatic effect, it has been hypothesized that the activated Purastat nanostructure favors the cell and tissue proliferative process since the similarity of the activated Purastat 3-D nanostructure with the natural extracellular matrix (ECM-SM) scaffold material would result in an adequate adherence of cells and regenerative tissues, achieving more effective healing of the mucosa. Based on this hypothetical re-epithelizing property of Purastat, we decided to use it in this patient, achieving mucosal healing and symptoms improvement.

1 January 2016 in World Journal of Gastrointestinal Endoscopy
Verified
Journal Article
Open access
RMRoberto Di Mitri
Roberto Di Mitri
FMFilippo Mocciaro
Filippo Mocciaro
SPSocrate Pallio
Socrate Pallio
GPGiulia Maria Pecoraro
Giulia Maria Pecoraro
ATAndrea Tortora
Andrea Tortora
AMAttilio Maurano
Attilio Maurano
To report data on Dilation-Assisted Stone Extraction (DASE) use in clinical practice and its efficacy and safety trough three Italian referral centers for biliopancreatic diseases treatment. From January 2011 to December 2015 we collected data on 120 patients treated with DASE. Technical success was obtained when the endoscopist was able to place the balloon trough the papilla inflating the balloon until the final diameter for an adequate time (at least 30 s). Clinical success was obtained after complete stone removal (no remaining stones were visible at the cholangiogram). Forty-nine male (40.8%) and 71 female (59%) were enrolled. The mean age was 67.8 years ± 15.7. The mean common bile duct (CBD) dilation was 19.2 mm ± 3.9 and the mean size of stones 15.8 ± 2.9. DASE was applied as first approach in 38% (62% after initial failure of stones extraction). Technical and clinical success was of 91% and 87% respectively. In those in which DASE failed alternative treatment were adopted. After DASE 18% of patients experienced a complication (bleeding 9%, pancreatitis 8%, perforation 0.8%). At univariable analysis, elective endoscopic retrograde cholangiopancreatography (P = 0.031), DASE as first approach (P = 0.032), and cannulation of major papilla followed by guidewire insertion (P = 0.004) were related to low risk of complications. Pre-cut was related to an increased risk of complications (P = 0.01). DASE allowed a higher first-session success rate and can be consider a valid alternative to endoscopic sphincterotomy not only for bigger CBD stones.

21 September 2021 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
MGMario Gagliardi
Mario Gagliardi
MSMariano Sica
Mariano Sica
GOGiovanni Oliviero
Giovanni Oliviero
AMAttilio Maurano
Attilio Maurano
CZClaudio Zulli
Claudio Zulli

19 March 2021 in Endoscopy
Verified
Conference Paper
Closed access
OLO Labianca
O Labianca
MSM Sica
M Sica
CZClaudio Zulli
Claudio Zulli
AMA Maurano
A Maurano
Aims Many possible causes of bleeding from upper and lower gastro-intestinal (GI) tract, are burdened by significant morbidity and mortality. Lately innovative topical hemostatic agents have been developed for endoscopic use. The aim of report is demonstrate efficacy and safety of PuraStat, a new absorbable hemostatic, to control, alone or in association with a second hemostatic technique, an active GI bleeding. Methods From October 2018 to September 2020, we observed a case series of 24 patients (15 males, 9 females; range age 44-87 years; mean age 69.8 years) admitted to our Digestive Endoscopy Unit, with anemization due to an active GI bleeding. In particular, 10 patients showed melena and 3 had hematemesis for gastric or duodenal active peptic ulcer, 2 patients had melena after Vater ampulla’s sphincterotomy, 9 patients presented hematochezia after polipectomy or mucosectomy in the colon. Ten patients were on antiplatelet/anticoagulant therapy (4 aspirin and 6 NOAC). PuraStat, a gel used in GI endoscopy to control venous and arteriolar bleedings, was used for primary haemostasis during emergency endoscopy. Results In our case series, PuraStat was used alone as first hemostatic technique and was effective in haemostasis in 25 % of cases (6/24), and it was also used as second hemostatic technique after injective or clipping and was effective in haemostasis in 75 % of cases (18/24). In all cases, we used a layer of PuraStat applying in a targeted manner about 2,5 ml. of transparent gel, and complete stable control of bleeding was achieved in all patients. No technical difficulties in application encountered, and no incidences of catheter blockage. No complication or delayed bleeding occurred. There were no instances of allergic reaction. Conclusions According to our experience, PuraStat is an effective, safe and easy to use hemostatic agent for management in different types of active GI bleeding, reducing risk of delayed bleeding. Citation: Labianca O, Sica M, Zulli C et al. eP3 USE OF PURASTAT IN MANAGEMENT OF GASTRO-INTESTINAL BLEEDING: OUR EXPERIENCE. Endoscopy 2021; 53: S97. Publication Date: 19 March 2021 (online) © 2021. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

4 January 2023 in Endoscopy
Verified
Journal Article
Open access
PDF file
CZClaudio Zulli
Claudio Zulli
Mario GagliardiMario Gagliardi
Mario Gagliardi
MFMichele Fusco
Michele Fusco
CACarmela Abbatiello
Carmela Abbatiello
MSMariano Sica
Mariano Sica
AMAttilio Maurano
Attilio Maurano
A 54-year-old man complaining of massive rectal bleeding and severe anemia was referred to our endoscopic center by the surgical unit. He had undergone stapled hemorrhoidectomy with Longo’s technique 3 weeks before, and had received topical steroid and mesalamine therapy for 1 week without clinical improvement. Rectosigmoidoscopy was scheduled and performed, showing a 3-cm dehiscence caused by impaired or delayed wound healing at the dentate line ([Fig. 1]). During the same procedure, 3 ml of the novel hemostatic gel Purastat was applied to obtain formation of a synthetic clot covering the entire dehiscence area. No bleeding or other complications were observed during or after the procedure ([Fig. 2]). Four weeks later, the patient underwent scheduled follow-up rectosigmoidoscopy, which showed scarring of the area with complete mucosal healing ([Fig. 3]). No bleeding, tenesmus, or other symptoms were reported by the patient ([Video 1]). Video 1 Endoscopic application of a novel hemostatic gel to treat wound dehiscence after stapled hemorrhoidectomy. Wound dehiscence is an early complication of stapled hemorrhoidectomy, with a prevalence of 3 %–5 %; it has been attributed to malfunctioning staplers and surgical inexperience, and surgical revision is often required [1]. Purastat is an uncolored, fully synthetic, viscous peptide hydrogel that self-assembles into fibers forming a sort of extracellular matrix; this matrix then acts as a mechanical barrier on the bleeding source, providing a hemostatic effect [2]. In addition to the known hemostatic effect, it has been hypothesized that the similarity of the 3 D nanostructure of activated Purastat to the natural extracellular matrix scaffold material favors cell and tissue proliferative processes, leading to more effective mucosal healing [3]. This treatment may become a valid alternative to revision surgery in patients with wound dehiscence following stapled hemorrhoidectomy. Endoscopy_UCTN_Code_CCL_1AD_2AJ Article published online: 17 March 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany